FOR US HEALTH CARE PROFESSIONALS ONLY
Prescribing Information
APOKYN® (apomorphine hydrochloride injection)GOCOVRI® (amantadine) extended-release capsulesMYOBLOC® (rimabotulinumtoxinB) injectionOXTELLAR XR® (oxcarbazepine) extended-release tabletsQELBREE® (viloxazine extended-release capsules)TROKENDI XR® (topiramate) extended-release capsulesXADAGO® (safinamide) tabletsONAPGOTM (apomorphine hydrochloride), for subcutaneous infusion
Adverse Event/Product Complaint
To report a suspected adverse event or product complaint, contact us at 1-866-398-0833 or email medinfo.supernus@apceris.com.
Connect With Us
Supernus Medical Affairs Logo
FOR US HEALTH CARE PROFESSIONALS ONLY
Supernus Medical Affairs LogoMenu Toggle
FIND AN MSLArrow RightSUBMIT AN INQUIRYArrow Right
Quick Link
QUICK LINKS

ATTENTION-DEFICIT/HYPERACTIVITY
DISORDER (ADHD)

PUBLICATIONSCONGRESS POSTERSEDUCATIONAL RESOURCESOUR PRODUCT

Select a section to view materials

PUBLICATIONS

OUR PRODUCT

QELBREE® (viloxazine extended-release capsules)

QELBREE is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients age 6 years and older.1

PRESCRIBING INFORMATION
VISIT QELBREE WEBSITE
HCP WEBSITE

Reference: 1. QELBREE® (viloxazine extended-release capsules). Package insert. Supernus Pharmaceuticals, Inc.

Supernus Logo
Research & DevelopmentConnect With UsTerms of UsePrivacy PolicyCookie Policy

This site is intended for US health care professionals.
The content on this website is intended for informational purposes only and should not be used as the sole basis for patient care decisions.

Supernus Pharmaceuticals, Inc.
9715 Key West Avenue, Rockville, MD 20850
(301) 838-2500
info@supernus.com

© 2025 Supernus Pharmaceuticals, Inc.